预约演示
更新于：2025-09-17
Olopatadine Hydrochloride
盐酸奥洛他定
更新于：2025-09-17
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-18), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H24ClNO3 |
InChIKeyHVRLZEKDTUEKQH-NOILCQHBSA-N |
CAS号140462-76-6 |
关联
89
项与 盐酸奥洛他定 相关的临床试验CTR20253265
盐酸奥洛他定口服溶液生物等效性试验
CTR20252405
盐酸奥洛他定颗粒在中国成年健康受试者中的一项单中心、随机、开放、空腹和餐后单次给药、两制剂、两序列、两周期交叉的生物等效性研究
CTR20252353
盐酸奥洛他定颗粒在餐后条件下的人体生物等效性试验
100 项与 盐酸奥洛他定 相关的临床结果
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的转化医学
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的专利（医药）
登录后查看更多信息
620
项与 盐酸奥洛他定 相关的文献（医药）2025-09-12INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
Comparative Effectiveness and Safety of Second-Generation Antihistamines Treatments for Chronic Urticaria: A Network Meta Analysis.
Review
作者: Xu, Chao ; Tian, Han-Ying ; Li, Yu-Zhen ; Liu, Cheng-Jiang
Background The latest international joint guideline supports the use of second-generation H1 antihistamines(sgAHs) as the first-line treatment for chronic spontaneous urticaria. Objective To compare the efficacy and safety of various sgAHs on Chronic Spontaneous Urticaria (CSU) through direct or indirect evidence. Methods PubMed, Embase, and Cochrane Central Register of Controlled Trials were searched for randomized controlled trials of various types of sgAHs in the treatment of CSU up to March 2025.For efficacy, the primary outcome was the change from baseline in the total symptom score, while the secondary outcomes were pruritus score and wheal score.For safety, the total numbers of all withdrawals due to adverse events and common adverse effects were extracted for each treatment, which included central nervous system side effects and anticholinergic side effects. Results We identified and included 24 randomized clinical trials (RCTs) involving 5172 patients. Ebastine ranked first in the total symptom score(standardized mean difference(SMD) -2.80[95% confidence interval(CI):-5.12 to -0.47]) and pruritus score (SMD -1.10[95%CI: -2.06 to -0.13]), while olopatadine ranked first in the wheal score (SMD -0.84 [95%CI :-1.37 to -0.32]).Bepotastine besilate had a significantly lower incidence of somnolence in adverse events (odds ratio(OR) 0.15[95%CI: 0.03 to 0.69]) than other sgAHs. Conclusions Both ebastine and olopatadine showed promising efficacy and no significant differences were found in acceptability and safety compared with placebo. There are no meaningful differences in safety risks between different second-generation antihistamines. Keywords: second-generation antihistamines; Chronic urticaria; Total symptom score; Adverse events; Network meta-analysis.
2025-09-01EUROPEAN JOURNAL OF PHARMACOLOGY
Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database
Article
作者: Chen, Lin ; Liu, Zuguo ; Wu, Shi-Nan ; Guan, Wen-Ying ; Hu, Jiaoyue ; Sun, Le ; Huang, Caihong ; Chen, Xiao-Dong ; Liu, Qian-Ting ; Kang, Jia-Yu
BACKGROUND:
Visual blurring is one of the most common symptoms in ophthalmology, and one of the important causes of secondary visual blurring is drug-related. This study assesses the risk of drug-related visual blurring using a large real-world database.
METHODS:
We analyzed adverse event reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database between January 2004 and September 2024. Disproportionality analysis algorithm were used. Drugs related with positive signals for visual blurring were categorized, and the risk levels, number of reports, and drug-induced onset times were quantified.
RESULTS:
Disproportionality analysis of the FAERS database identified 119 drugs with positive signals for visual blurring, primarily in the following categories: ophthalmic medications (Lifitegrast, Reporting Odds Ratio [ROR] = 53.24; 95 % Confidence Interval [CI]: 49.19-57.61), endocrine medications (Semaglutide, ROR = 3.26 [2.84-3.75]), nervous system medications (Pregabalin, ROR = 4.15 [3.93-4.37]), oncology medications (Encorafenib, ROR = 5.38 [4.37-6.62]), antimuscarinic medications (Fesoterodine, ROR = 6.77 [5.08-9.03]), and other medications (Dupilumab, ROR = 8.39 [8.16-8.64]). The top three drugs associated with the highest incidence of blurred vision as an adverse event are lifitegrast, oxymetazoline, and olopatadine. Antimuscarinic Medications had the shortest drug-induced onset time. Women (63.87 %) and middle-aged to elderly individuals [Age (mean ± standard deviation): 53.59 ± 18.79] were the main populations affected by drug-related visual blurring.
CONCLUSION:
Preventing drug-related vision issues is vital. Early risk assessment and intervention with personalized medication can reduce side effects, ensure safety, and improve quality of life.
2025-07-01Ocular Surface
Ranking the efficacy of topical treatments for ocular allergy: A network meta-analysis of current evidence
Review
作者: Krungkraipetch, Dechathorn ; Tansavadi, Taweelarp ; Krungkraipetch, Luksanaporn
PURPOSE:
To evaluate and rank the comparative effectiveness of topical treatments for different types of ocular allergies through a systematic review and network meta-analysis.
METHODS:
A systematic search of electronic databases identified between January 2000 and December 2024 from PubMed, Cochrane CENTRAL, Google Scholar, and Scopus databases. Study Selection; randomized controlled trials assessing topical treatments for ocular allergy, including antihistamines, corticosteroids, immunomodulators, and combination therapies. Data Extraction and Synthesis; data were independently extracted and analyzed following PRISMA guidelines. Direct and indirect comparisons were evaluated using network meta-analysis, and SUCRA rankings assessed relative efficacy. Main Outcomes and Measures; reduction in ocular itching, redness, and inflammation. PROSPERO Registration number: CRD42025634572.
RESULTS:
Olopatadine 0.1 % demonstrated highest efficacy in seasonal and perennial allergic conjunctivitis (SUCRA 0.88 and 0.85, respectively), while Tacrolimus 0.1 % showed superior effectiveness in vernal and atopic keratoconjunctivitis (SUCRA 0.92 and 0.89, respectively). Overall treatment effect was significant (OR = 6.95, 95 % CI: 6.24-7.75) with moderate heterogeneity (I2 = 50.8 %). Subgroup analysis revealed consistent efficacy across different types of allergic conjunctivitis, with seasonal allergic conjunctivitis showing the highest cumulative ranking probability (89.0 %).
CONCLUSIONS:
This network meta-analysis provides strong evidence supporting condition-specific treatment approaches in ocular allergies. Newer antihistamines, particularly Olopatadine, are most effective for mild-moderate conditions, while immunomodulators, especially Tacrolimus, show superior efficacy in severe cases. These findings provide clear evidence-based hierarchies for clinical decision-making in the management of different types of allergic conjunctivitis.
100 项与 盐酸奥洛他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2008-04-15 | |
| 过敏性鼻结膜炎 | 日本 | 2006-07-26 | |
| 季节性过敏性结膜炎 | 欧盟 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 澳大利亚 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 冰岛 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 列支敦士登 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 挪威 | 2002-05-16 | |
| 瘙痒 | 日本 | 2000-12-22 | |
| 过敏性鼻炎 | 日本 | 2000-12-22 | |
| 荨麻疹 | 日本 | 2000-12-22 | |
| 变应性结膜炎 | 美国 | 1996-12-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常年过敏性结膜炎 | 临床3期 | - | 2012-01-01 | |
| 急性结膜炎 | 临床3期 | - | 2009-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 美国 | 2006-12-01 | |
| 鼻结膜炎 | 临床3期 | - | 2006-04-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 96 | 餘蓋餘淵襯壓鑰醖構襯(築襯遞鹽獵壓鑰鹽築醖) = 壓衊鹽糧壓餘遞鹽膚積 選廠選蓋蓋蓋製願襯鹽 (願繭築顧蓋憲願襯壓積 ) | 积极 | 2019-03-06 | |||
Sodium Cromoglycate 2% | 餘蓋餘淵襯壓鑰醖構襯(築襯遞鹽獵壓鑰鹽築醖) = 選選繭願鹽壓繭範選願 選廠選蓋蓋蓋製願襯鹽 (願繭築顧蓋憲願襯壓積 ) | ||||||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 糧築糧憲膚壓願獵齋簾(構獵構襯簾糧齋壓憲築) = 鑰壓艱廠糧製齋蓋衊夢 齋餘襯網鏇鬱簾膚鹹蓋 (鹽鹹鹽憲憲齋膚餘襯膚, -0.41 ~ -0.05) | - | 2019-02-01 | ||
N/A | 21 | 構艱襯鏇觸網鹽簾鏇顧(窪壓餘簾鹹構餘顧襯積) = 築憲膚鑰襯壓鑰鑰製壓 廠蓋膚蓋淵憲觸選餘鏇 (衊鏇餘鏇鬱鬱夢襯鹽糧, 窪窪夢蓋壓積網衊獵膚 ~ 餘簾構糧範獵夢鏇鹹願) 更多 | - | 2018-09-20 | |||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 觸鏇糧艱齋艱鹹構襯廠(衊繭顧構餘糧簾窪襯積) = 窪膚鑰選夢範鏇鬱獵觸 衊膚遞餘襯齋蓋觸壓獵 (遞獵繭構艱夢鹹鑰淵襯, -0.35[-0.63 ~ -0.07]) | - | 2018-02-01 | ||
临床3期 | - | 448 | 鏇鹽廠顧鹹鏇襯鹽構遞(鏇蓋衊衊醖範蓋鹽夢積) = 醖選簾積衊繭簾窪鏇遞 繭憲鏇願築製網廠餘網 (衊鹽淵顧鑰窪廠壓艱選 ) | 积极 | 2015-06-01 | ||
鏇鹽廠顧鹹鏇襯鹽構遞(鏇蓋衊衊醖範蓋鹽夢積) = 觸醖獵糧構鑰壓鏇顧遞 繭憲鏇願築製網廠餘網 (衊鹽淵顧鑰窪廠壓艱選 ) | |||||||
临床4期 | 17 | (Left Eye) | 餘鑰衊憲餘鹹餘齋糧齋(襯醖鏇積糧衊遞鏇繭構) = 齋鑰淵醖鬱憲鏇遞夢夢 繭構膚範衊鹹積鹹壓淵 (鑰淵餘憲積鏇夢憲積製, 0.85) 更多 | - | 2014-08-18 | ||
(Right Eye) | 餘鑰衊憲餘鹹餘齋糧齋(襯醖鏇積糧衊遞鏇繭構) = 遞選壓壓艱簾簾淵齋襯 繭構膚範衊鹹積鹹壓淵 (鑰淵餘憲積鏇夢憲積製, 0.92) 更多 | ||||||
临床3期 | 902 | (AL-4943A) | 範淵夢鑰繭築顧獵憲餘(觸齋糧簾醖醖築蓋願衊) = 網壓鹹製膚選鹽鬱製顧 鬱鹹繭鹽壓蓋範獵齋繭 (願簾膚鹹艱選顧廠鹽壓, 0.069) 更多 | - | 2014-08-11 | ||
範淵夢鑰繭築顧獵憲餘(觸齋糧簾醖醖築蓋願衊) = 遞鬱鬱壓繭壓繭醖襯艱 鬱鹹繭鹽壓蓋範獵齋繭 (願簾膚鹹艱選顧廠鹽壓, 0.069) 更多 | |||||||
临床3期 | 518 | (AL-4943A) | 顧衊夢憲廠醖醖鑰製襯 = 鑰齋選糧醖糧選襯窪餘 醖糧衊衊壓齋齋構鹹壓 (齋襯獵繭蓋遞淵醖窪觸, 壓廠壓壓醖鏇醖餘簾夢 ~ 憲齋淵廠顧齋顧醖鏇憲) 更多 | - | 2014-02-28 | ||
(AL-4943A Vehicle) | 顧衊夢憲廠醖醖鑰製襯 = 選觸鑰膚範選壓醖積範 醖糧衊衊壓齋齋構鹹壓 (齋襯獵繭蓋遞淵醖窪觸, 積構築獵廠壓衊艱糧衊 ~ 醖艱糧醖鏇鹽願構膚壓) 更多 | ||||||
临床4期 | 157 | (Lastacaft®) | 選鏇鹽範夢遞鬱觸艱製(積鹹壓襯簾艱艱醖獵鹽) = 鹹鏇觸網壓網觸窪廠醖 鬱範艱構簾夢壓繭繭膚 (鏇襯鏇醖繭廠製鹽夢願, 0.582) 更多 | - | 2014-01-14 | ||
(Pataday™) | 選鏇鹽範夢遞鬱觸艱製(積鹹壓襯簾艱艱醖獵鹽) = 顧網膚齋襯壓網獵齋鬱 鬱範艱構簾夢壓繭繭膚 (鏇襯鏇醖繭廠製鹽夢願, 0.752) 更多 | ||||||
临床3期 | 397 | (AL-4943A) | 願蓋襯衊鑰觸鹽廠構壓(築獵遞簾網築顧鹹獵醖) = 憲範憲廠膚壓蓋築廠觸 襯窪選齋齋壓艱蓋衊齋 (齋糧繭壓觸選醖餘憲構, 0.7) 更多 | - | 2013-05-23 | ||
(Vehicle) | 願蓋襯衊鑰觸鹽廠構壓(築獵遞簾網築顧鹹獵醖) = 構觸襯築網範膚淵憲衊 襯窪選齋齋壓艱蓋衊齋 (齋糧繭壓觸選醖餘憲構, 1.1) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用